10% Owner Ansbert Gadicke Reports Sale of Werewolf Therapeutics Inc. Common Shares
Ansbert Gadicke, a 10% owner of Werewolf Therapeutics Inc., reported selling common shares. Other beneficial owners include MPM Oncology Innovations Fund LP and UBS Oncology Impact Fund L.P. The original filing is available via EDGAR, the SEC's system. This AI-generated news is for informational purposes and not financial advice.
Ansbert Gadicke, a 10% owner, reported a disposal of common shares of Werewolf Therapeutics Inc. Other reporting beneficial owners include MPM Oncology Innovations Fund LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., and MPM BioImpact LLC. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001231919-25-000564), on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
